DFE Pharma

Do you have questions about continuous manufacturing processes and their implementation? Dr. Sara Fathollahi is a Product Application Specialist at DFE Pharma and an expert in this topic. She holds a Bachelor of Science (BSc) in Biomedical Engineering from Science and Research University of Tehran (Iran), a Master of Science (MSc) in Biomedical Engineering and a Ph.D., Process Engineering from Graz University of Technology (Austria). Get in touch with our expert: https://lnkd.in/eEBwjT6X

We have been helping people to live healthier lives for over a century. Our journey started in 1900 with the foundation of the Hollandsche Melk Suikerfabriek, and 123 years later, our purpose remains true: Your medicines, our solutions. Moving to a healthier world. #Excipients #pharmaceuticals #biologics

Successful implementation of continuous manufacturing relies on in-depth understanding of how raw materials behave in these processes. Martti Hedman, CEO at DFE Pharma, discussed the benefits of implementing this technology and the importance of understanding raw materials, noting that many products are currently in the pipeline with the support of the FDA and other regulators. #ContinuousManufacturing #Excipients #Pharmaceuticals

Now introducing microcrystalline cellulose (MCC) with nitrite levels <0.035ppm! Looking for microcrystalline cellulose (MCC) with consistently low nitrite levels? DFE Pharma's Pharmacel® MCC portfolio now features nitrite values on the Certificate of Analysis with typical values <0.035ppm for each of our three grades: Pharmacel® 101, Pharmacel® 102, and Pharmacel® 112. - Ultra-low nitrite levels averaging below our level of quantitation (LOQ) of 0.035 ppm - Proven batch-to-batch consistency Download our brochure and discover the difference with Pharmacel®. Reliable. It’s as simple as that: https://lnkd.in/dMfcPUG8 #Nitrosamines #Excipients #Pharmaceuticals 

Being close to our customers and sharing valuable expertise is very important for us. Our Chinese team recently hosted two highly engaging oral solid dose seminars in Beijing and Chengdu this past April and June. Equipping participants with the knowledge to enhance their pharmaceutical development, we ensure they receive support for their formulation challenges while sharing insightful data and expertise obtained through our experts' research. We extend our heartfelt thanks to all participants for their engagement and dynamic discussions as well as our dedicated China Team! #China #Excipients #Pharmaceuticals 

Our Japanese team showcased our capabilities at Interphex, one of Asia's premier Pharma & Bio Tech events, held at Tokyo Big Sight East 3 Hall. Our booth drew significant interest, with numerous inquiries about our extensive range of excipient solutions designed to optimize drug formulation and delivery. Highlighting how we can expedite your formulation success Dr. Anilkumar Gandhi, Director of our Closer to the Formulation (C2F) Center of Excellence, joined the event. Don't miss the chance to connect with our experts and discover how DFE Pharma can enhance your pharmaceutical development and manufacturing objectives. https://lnkd.in/eEBwjT6X #Japan #Excipients #Pharmaceuticals 

The beginning of the summer is the perfect occasion for getting together and enjoying a day of connection, celebration and appreciation. On Thursday afternoon, our employees from Germany and the Netherlands came together for our Summer Event, an annual tradition that allows us to engage, share nice conversations, strengthen our relationships and enjoy delicious food and drinks. Thank you to all who attended and contributed to making this year's summer gathering a memorable and enjoyable experience. #Excipients #Pharmaceuticals 

On our latest research, we demonstrate how selecting the right excipients and using mini-blending technology will make continuous processing suitable for low-dosage formulations and low volume products. . In this study, conducted in partnership with Gericke Group and GSK, we show how high-end excipients can have a key role in the effectiveness of process intensification of the blending of active pharmaceutical ingredients (API) when using a semi-continuous mini-blending process.   By carefully selecting the appropriate excipients, and explaining their function, we optimized throughput while maintaining blend uniformity and powder structure. The mini-blending process aligns seamlessly with the desired throughput of a commercial Continuous Direct Compression (CDC) process.   Authors: Dr. Maarten Jaspers, Timo Roelofs, Dr. Bastiaan HJ Dickhoff (DFE Pharma), Alexandra Lohrmann, Florian Tegel, Bernhard Meir (Gericke), Muhammad Khalid Maqsood, Yunfei Li Song, Richard Elkes (GSK).   Published on the International Journal of Pharmaceutics: X https://lnkd.in/d4UaEzqa

Greetings from Shanghai! Meet our team at CPHI China and let us support you with our high-quality excipients and dedicated solutions. Don't miss our talk on nitrosamine risk mitigation tomorrow at 9:30h, with the participation of Dr. Bastiaan HJ Dickhoff, Innovation and Technical Solutions Director at DFE Pharma. Visit us at booth E342.

The respiratory market is continuously evolving, with an increasingly greater emphasis on the importance of speed to market. As a result, DFE Pharma is committed to enhancing our service offerings, enabling us to be your trusted partner both today and in the future. Let's collaborate to expedite and de-risk your inhalation product development. Contact us: www.dfepharma.com/contact